DOD Vision, Translational Research Award | W81XWH 21 VRP TRA

Opportunity Information: Apply for W81XWH 21 VRP TRA

The DOD Vision, Translational Research Award (FY21 VRP TRA) is a U.S. Department of Defense funding opportunity designed to push vision-related research past early discovery and into practical clinical use for conditions tied to military-relevant trauma. The core goal is translational impact: taking promising findings and moving them toward real-world tools that can prevent, diagnose, reduce, or treat eye injuries and visual dysfunction that arise from traumatic events relevant to service members. Rather than supporting basic science in isolation, this award emphasizes development-oriented work that can credibly lead to a product or practice change that clinicians could ultimately use.

This program specifically looks for projects that lay out a clear and believable pathway from a discovery to an outcome such as a new drug, a medical device, or even clinical practice guidelines, with the expectation that the work will mature to the point of being ready for definitive testing in clinical trials. In other words, the proposed research should not stop at proof-of-concept alone; it should be structured around the concrete steps needed to reach clinical readiness, including the kinds of validation, optimization, and translational planning that allow a therapy or technology to move into regulated human testing.

A major feature of the award is its strong alignment with U.S. Food and Drug Administration requirements when the project involves a regulated product. If the research is aimed at a drug or device, the opportunity anticipates that an Investigational New Drug (IND) application and/or an Investigational Device Exemption (IDE) application will be submitted during the project period or by the end of the period of performance. To make that feasible, applicants are expected to build a team that includes at least one collaborator with real expertise in FDA regulatory pathways, so the project is guided by regulatory strategy from the start rather than treated as an afterthought. This is meant to reduce the risk that a technically promising concept stalls because it lacks the documentation, study design, quality considerations, or regulatory framing needed to advance to clinical trials.

Administratively, the opportunity is issued by the Department of Defense, Department of the Army, through USAMRAA, under funding opportunity number W81XWH 21 VRP TRA. It is categorized as discretionary and supports science and technology or other research and development activities under CFDA 12.420. The funding mechanisms listed are cooperative agreements and grants, signaling that awards may involve varying degrees of agency involvement depending on the specific instrument used. Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility details that may be provided in the full announcement text. The opportunity was created on May 14, 2021, with an original closing date of November 16, 2021. The posting indicates an expected single award, and the award ceiling is listed as 0, which typically suggests the maximum amount was not specified in the summary record and would need to be confirmed in the full solicitation materials.

Overall, this award targets later-stage, translation-focused vision trauma research with a clear product-development or clinical-implementation trajectory, and it places unusual emphasis on regulatory preparedness, including planning toward IND/IDE submission when relevant.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Vision, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 14, 2021.
• Applicants must submit their applications by Nov 16, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 VRP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: